Saturday, April 18, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

Study reveals likely reason for ‘stealth’ Omicron’s recent success

The ability to spread more easily from person to person appears to be the superpower that is driving an upstart sibling of the Omicron variant into wide circulation, a group of scientists has surmised.

That conclusion about the virus known as “stealth Omicron” is explained in a brief report published this week by the New England Journal of Medicine. It’s based on the team’s finding that the virus, whose official name is BA.2, is only slightly better than the dominant BA.1 at evading the protective effects of COVID-19 vaccines.

Source: LA Times

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

Policy Shift in Peptide Regulation

Semaglutide and the Expansion Problem: When One Trial Becomes a Platform

Semaglutide and the Expansion Problem: When One Trial Becomes a Platform

Semaglutide has moved beyond its original indication and now sits at the center of a widening set of clinical questions: cardiovascular risk, kidney disease progression, and even neurodegeneration. The question is no longer whether the drug lowers glucose or reduces weight—it does—but how far those effects extend across systems, and whether evidence from one population can be translated into another without distortion. Large, well-powered trials have produced consistent signals, yet those signals are now being applied in contexts that were...

Read more

Join Our Newsletter!